Bulletin du Cancer
MENUHormonotherapy in breast cancer with bone metastasis Volume 84, issue 9, Septembre 1997
Figures
- Key words: breast cancers, bone metastasis, progestins.
- Page(s) : 891-4
- Published in: 1997
Hormonotherapy in metastatic breast cancer is actually performed using 3 therapeutic classes: antiestrogen as tamoxifen (TAM), progestins, megestrol acetate (MA) and medroxyprogesterone acetate (MPA), aromatase-inhibitors as aminoglutethimide (AG). We investigated therapeutic efficacy of progestins compared to other hormonotherapies in case of breast cancer with bone metastasis. In a litterature review, we found ten randomized trials comparing: MPA versus AG, MPA versus MA, MPA versus TAM, MA versus AG versus TAM. The results show an advantage on the response rate using MPA; the usual dose was 900-2000 mg daily. MPA mode of action can explain these results since they combine gestagenic, androgenics and glucocorticoid effects.